Elevated expression of FOXC2 mRNA and protein correlate with tumor aggressiveness, metastasis, and poor prognosis in many cancer types, including breast cancer [15,16], prostate cancer [17], pancreatic cancer [18], colon cancer [19], gastric cancer [20], non-small-cell lung cancer [21,22], ovarian cancer [23,24], esophageal squamous cell carcinoma [25], osteosarcoma [26], glioma [27], glioblastoma [28], melanoma [29], hepatocellular carcinoma [30], and extrahepatic cholangiocarcinoma [31]. This evidence concerns the gene FOXC2 and neoplasm.